Monitor AURORA Phase 3 topline data in 2H 2027 as the primary catalyst. TVB-3567 Phase 2 initiation before year-end 2026 is a near-term pipeline milestone. The cash runway through mid-2029 reduces near-term financing risk.
Price Chart
Executive Summary
Sagimet Biosciences filed an 8-K with an updated investor presentation on October 22, 2026. The presentation highlights the first patient dosed in the AURORA Phase 3 acne trial for denifanstat in the US (topline results expected 2H 2027), positive Phase 3 data from the China partner Ascletis, and progress on the follow-on FASN inhibitor TVB-3567. The company reported $257.6M cash as of 6/30/2026 plus $115M from a September 2026 offering, funding operations through mid-2029. No new financial results or guidance were provided.
Key Facts
- First patient dosed in AURORA Phase 3 acne trial (US) in October 2026; topline results expected 2H 2027.
- Denifanstat met all primary and secondary endpoints in Phase 3 trial (ASC40-303) in China; NDA accepted by NMPA in December 2025.
- TVB-3567 Phase 1 FIH trial initiated June 2025; SAD/MAD/food effect dosing complete; Phase 2 expected to start before end of 2026.
- Cash position: $257.6M as of 6/30/2026 plus $115M from September 2026 offering; expected to fund operations through mid-2029.
- Denifanstat composition of matter patent expires 2032 (potential PTE to 2037); TVB-3567 patent expires 2035 (potential PTE to 2038).
- Further MASH development only upon securing non-dilutive funding.
Financial Impact
No new financial results or guidance. Cash runway extended through mid-2029 via $115M September 2026 offering.
Risk Factors
- Phase 3 acne trial failure or weaker-than-expected efficacy/safety.
- Reliance on partner Ascletis for China NDA approval and commercialization.
- MASH development contingent on non-dilutive funding; no guarantee secured.
- Dilution from September 2026 offering already completed.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-428314 |
| Document: d124492d8k.htm | 0001193125-26-428314 |
| Document: 0001193125-26-428314-index-headers.html | 0001193125-26-428314 |
| Document: 0001193125-26-428314-index.html | 0001193125-26-428314 |
| Document: 0001193125-26-428314.txt | 0001193125-26-428314 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $9.95 $9.58 | ▼ −3.72% | ▼ −3.20% | $10.42 (+4.72%) |
Oct 7, 2026 19d ago | SC 13G | $8.92 $8.93 | ▲ +0.11% | ▼ −0.49% | $10.42 (+16.82%) |
Oct 1, 2026 26d ago | Press Release | $9.14 $9.03 | ▲ +1.20% | ▲ +1.88% | $10.42 (−14.00%) |
Sep 30, 2026 27d ago | Press Release | $9.88 $9.37 | ▲ +5.16% | ▲ +5.34% | $10.42 (−5.47%) |
Sep 30, 2026 27d ago | 8-K | $9.88 $9.37 | ▼ −5.16% | ▼ −5.34% | $10.42 (+5.47%) |
Sep 22, 2026 5w ago | Institutional Cluster | $11.09 $10.42 | ▼ −6.04% | ▼ −5.32% | $10.42 (−6.04%) |
Aug 25, 2026 9w ago | Press Release | $10.29 $10.86 | ▲ +5.54% | ▲ +5.52% | $10.42 (+1.26%) |
Aug 11, 2026 11w ago | 8-K | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.42 (+9.45%) |
Aug 11, 2026 11w ago | Press Release | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.42 (+9.45%) |
Jul 22, 2026 13w ago | Insider Cluster | $7.01 $7.07 | ▲ +0.86% | ▲ +0.75% | $10.42 (+48.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers